A composition for controlling or preventing progression of glaucoma comprisesa material that reduces or inhibitsproduction of a TGF-.beta. isoform or a chemokine or cytokine that stimulatesexpression of a TGF-.beta. isoform. The material cancomprise a dissociated glucocorticoid receptor agonist ("DIGRA"), a prodrugthereof, a pharmaceutically acceptable salt thereof, or apharmaceutically acceptable ester thereof. The composition can furthercomprise an antagonist to TGF-.beta.. It is administered to apatient who has undergone glaucoma filtration surgery to ensure a functioningfiltering bleb following such surgery.
